E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients with atherosclerotic coronary artery disease (CAD) |
|
E.1.1.1 | Medical condition in easily understood language |
patient who have suffered a myocardial infarction |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to determine whether long-term treatment with colchicine reduces rates of cardiovascular events in patients after myocardial infarction (MI) |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to determine the safety of long-term treatment with colchicine in this patient population. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Males and females, at least 18 years of age , capable and willing to provide informed
consent;
Patient must have suffered a documented acute MI within the last 30 days;
Patient must be treated according to national guidelines (including anti-platelet therapy,
statin, renin-angiotensin-aldosterone system (RAAS) inhibitor (preferably angiotensinconverting-
enzyme (ACE) inhibitor) and beta-blocker when indicated);
Patient must have completed any planned percutaneous revascularization procedures
associated with his/her qualifying MI;
Female patient is either not of childbearing potential, defined as postmenopausal for at
least 1 year or surgically sterile, or is of childbearing potential and practicing at least one
method of contraception and preferably two complementary forms of contraception
including a barrier method (e.g. male or female condoms, spermicides, sponges, foams,
jellies, diaphragm, intrauterine device (IUD)) throughout the study and for 30 days after
study completion;
Patient is judged to be in good general health as determined by the principal investigator;
Patient must be able and willing to comply with the requirements of this study protocol |
|
E.4 | Principal exclusion criteria |
Patient with a poorly controlled medical condition, such as New York Heart Association
Class III-IV heart failure, a left ventricular ejection fraction of less than 35%, recent
stroke (within the past 3 months), or any other condition which, in the opinion of the
investigator, would put the patient at risk if participating in the study
Patient with a prior coronary artery bypass graft within the past 3 years, or planned;
Patient with a Type 2 index MI (secondary to ischemic imbalance);
Patient currently in cardiogenic shock or with hemodynamic instability;
Patient with a history of cancer or lymphoproliferative disease within the last 3 years,
other than a successfully treated non-metastatic cutaneous squamous cell or basal cell
carcinoma and/or localized carcinoma in situ of the cervix;
Patient with inflammatory bowel disease (Crohn’s disease or ulcerative colitis) or patient
with chronic diarrhea;
Patient with pre-existent progressive neuromuscular disease or patient with CPK level > 3
times the upper limit of normal (unless due to MI, which is allowed) as measured within
the past 30 days and determined to be non-transient through repeat testing
Patient with any of the following known parameters, as measured within the past 30 days, and determined to
be non-transient through repeat testing:
- hemoglobin < 115g/L,
- white blood cell count < 3.0 X 109/L,
- platelet count <110 X 109/L,
- ALT > 3 times the upper limit of normal (ULN),
- total bilirubin > 2 times ULN (unless due to Gilbert syndrome, which is
allowed)
- Creatinine > 2 times ULN;
Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease;
Female patient who is pregnant, or breast-feeding or is considering becoming pregnant
during the study or for 6 months after the last dose of study medication;
Patient with a history of clinically significant drug or alcohol abuse in the last year;
Patient is currently using or plans to begin chronic systemic steroid therapy (oral or
intravenous) during the study (topical or inhaled steroids are allowed);
Patient currently taking colchicine for other indications (mainly chronic indications
represented by Familial Mediterranean Fever or gout). There is no wash-out period
required for patients who have been treated with colchicine and stopped treatment prior
to enrolment;
Patient with a history of an allergic reaction or significant sensitivity to colchicine;
Patient who has used an investigational chemical agent less than 30 days or 5 half-lives
prior to the Screening visit (whichever is longer);
Patient is considered by the investigator, for any reason, to be an unsuitable candidate for
the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the time from randomization to the first event of cardiovascular death, resuscitated cardiac arrest, acute MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1) at 50% of primary endpoints ( interim analysis)
2) at end of the study |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints will consist of times to
total mortality to components of the primary endpoint, and to the composite of cardiovascular
death, resuscitated cardiac arrest, acute MI, or stroke. Recurrent cardiovascular events will also
be evaluated. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) at 50% of primary endpoints ( interim analysis)
2) at end of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 80 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Canada |
Chile |
Colombia |
France |
Germany |
Italy |
Lebanon |
Portugal |
Spain |
Tunisia |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Since it is an event driven trial LVLS will be performed after obtaining 301 events. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |